BusinessExosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider NetworkBy Nasdaq OMXDec 4, 2017, 12:33 PM UTC
BusinessExosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore TestBy Nasdaq OMXNov 27, 2017, 1:16 PM UTC
BusinessExosome Diagnostics to Present a Novel Atlas of Exosomal mRNA and Long non-coding RNA Across Biofluids at American Society of Exosomes and Microvesicles Annual MeetingBy Nasdaq OMXOct 11, 2017, 11:30 AM UTC
BusinessCareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic TestsBy Nasdaq OMXAug 24, 2017, 12:59 PM UTC
BusinessExosome Diagnostics Launches the MedOncAlyzer™ Pan-Cancer PanelBy Nasdaq OMXAug 9, 2017, 1:02 PM UTC
BusinessExosome Diagnostics Presents Breakthrough Liquid Biopsy Technologies at BIO International ConventionBy Nasdaq OMXJun 22, 2017, 3:55 PM UTC
